Reuben Ben-David

Reuben Ben-David: Gem/Doce is gaining grounds in the treatment of NMIBC

Reuben Ben-David, Society of Urological Oncology (SUO) fellow at the Mount Sinai Hospital NYC, shared on X:

“Excited about our latest publication! Gem/Doce induction plus maintenance is superior to induction only.

The use of 2 grams of gemcitabine improved all grades of recurrence but didn’t decrease high-grade recurrences over 1 gram of gemcitabine.

Gem/Doce is gaining grounds in the treatment of NMIBC.” .

Reuben Ben-David

Source: Reuben Ben-David/X